Kromek Group PLC (LON:KMK)

Kromek Group PLC (LON:KMK)

Share Price
26.15 p
-0.35 (-1.32 %)
Market Cap
£90.10 m
Proactive Investors - Run By Investors For Investors

Kromek Group PLC

Kromek Group plc is a leading developer of radiation detection solutions based on high performance sensor materials, primarily cadmium zinc telluride (CZT), for applications within the medical, nuclear and security screening markets. Our solutions provide high resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous...

Market: AIM:KMK
52-week High/Low: 31.95p / 19.47p
Sector: Technology Hardware & Equipment
Market Cap: £90.10 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Kromek Group PLC

Kromek Group PLC Snapshot

Vision and Strategy

The Board's current business strategy comprises the following aspects:

Our Vision
To be the world-leading provider of multispectral radiation detection products and technologies to enable customers and users to take better decisions based on better information.

Increased product integration
Kromek aims to satisfy increasing customer demand for more integrated and complete solutions. Following the acquisition of eV Products, the Board plans to fully integrate its products into the Group's existing offering and develop enhanced solutions.

Further commercialisation of the core technology
The Group plans to further commercialise its core technology through new product development for existing core markets, expansion into new geographical markets with existing products, including the opening of a sales office in Germany, and through licensing its technology in new market sectors.

In particular, the Directors believe that new modalities of nuclear detection, including further forms of cancer screening, as well as a continuing trend for networked sensors will create significant additional opportunities.

Enhanced OEM relationships
The Group will continue to supply its products and subcomponents to OEMs, and will aim to convert its current development contracts into long-term supply agreements. Additionally, the Group will target the development of new key relationships with further OEM partners in its target markets.


Kromek has a portfolio of products for specific detection, identification and quantification of radioactive materials, which are differentiated by their sensitivity, high resolution and small form factor allowing unprecedented flexibility in deployment. Applications include civil radiation detection, industrial process control, environmental monitoring and personal detection use for the public.

For more information, please click here


Kromek offers detectors and subcomponents for OEM customers in the medical imaging market including CT, SPECT, PET and Bone Mineral Densitometry. Colour imaging enables earlier, more reliable detection of cancer, cardiac conditions and osteoporosis with lower doses of radiation - resulting in better patient outcomes.

For more information, please click here


OEM Solutions



Standard ASICs for x-ray and gamma ray applications

Modern high performance detection systems depend on state-of-the-art ASIC based readout electronics. Whether it is high-energy resolution, high-spatial resolution or high count rate, NOVA ASICs offer a combination of unsurpassed speed and functionality.

For more information, please click here


Kromek has a diverse technology base and is building expertise based on its core competence of materials technology and advanced x-ray imaging architecture. The company's ability to produce single crystals in the Cadmium Telluride (CdTe) family of materials, on a commercial basis, has enabled it to exploit their energy selectivity in a range of innovative products having both imaging and non imaging applications.

For more information, please click here






Sir Peter Williams, CBE, FREng, FRS, Chairman, and chairman of the Audit Committee

He completed his MA degree and PhD at Cambridge, followed by a Lectureship at Imperial College. He then moved into industry, working at VG Instruments where he became Deputy Chief Executive and at Oxford Instruments, the first spin out from Oxford University, where he held the positions of Chief Executive Officer and Chairman. He also held the roles of Chairman of Isis Innovation Ltd, the technology transfer arm of Oxford University, Chairman of the National Physical Laboratory, Master of St. Catherine’s College Oxford and Vice President and Treasurer of the Royal Society. Other PLC experience includes serving as senior independent director of GKN plc and as a non-executive director of WS Atkins plc. He received a CBE in 1992 and was knighted in the Queen's Birthday Honours list of 1998. He is currently Chairman of the Daiwa Anglo Japanese Foundation in addition to his Kromek responsibilities.  

ms Arnab Basu





Dr Arnab Basu MBE, CEO, has a PhD in physics from Durham University, specialising in semiconducting sensor materials

Arnab held senior management positions in his family business, which manufactured materials for the electronics industry serving over 250 major telecommunications and consumer electronics manufacturers, including Siemens, GEC. He worked in commercial product development for Elmwood Sensors Ltd, (Honeywell Group, UK). A prominent figure within the business community, he was awarded Ernst and Young 'Entrepreneur of the Year' (2009) and received an MBE for services to regional development and international trade (2014).     

ms derek bulmer





Mr Derek Bulmer, Executive Director, Chief Financial Officer and in-house Counsel

A qualified Chartered Accountant and Barrister, Derek has worked with KPMG and undertaken a number of senior management roles with blue chip plc's including Bass plc, AWG plc and Ibstock plc. Additionally, and more recently, a number of roles as Finance Director of privately owned groups in both the IT and oil and gas industries have provided a wealth of experience in executing and managing business acquisitions plus significant aspects of the commercial and legal disciplines of corporate management.           

ms Lawrence kinet2





Mr Lawrence Kinet, Director and member of the Remuneration Committee

Lawrence has 40 years’ experience in the medical device and bio-pharmaceutical industry in leadership positions, most recently as Group Chief Executive of LMA International NV and, President of Smiths Medical, London. Lawrence has raised more than $100m in funding for early stage companies, taking one through an IPO, and made over $1bn worth of acquisitions. His career began at Baxter International, running a number of overseas operations eventually becoming President of Baxter's International Division. He holds a BSc from the University of Birmingham (UK) and an MBA from the University of Chicago.


ms graeme speirs





Dr. Graeme Speirs, Director and member of the Audit Committee

Graeme is an experienced entrepreneur and owner of the Polymer Holdings Group and Polymer N2, an investment company focused on UK start ups in the technology, life sciences and energy sectors. Graeme graduated with first class honours in chemistry and a PhD in molecular physics from Aberdeen University, and holds a masters degree in Technology and Economics from Birmingham University. Involved in the oil and gas industry, Graeme is an expert in the design and manufacture of polymer composite products.         

ms Jerel Whittingham2





Mr Jerel Whittingham, Director and Chairman of the Remuneration Committee

Jerel has extensive experience in investor, operational and strategy roles with technology rich companies including Incuvest LLC, Generics Group plc, Durlacher plc, Amphion Innovations plc, INMARSAT and a number of start-ups. He was appointed to the Board of Kromek Group plc in September 2013 and also served on the Board of DSC Ltd, a predecessor company of the group. Currently he combines NED and operational roles in technology growth companies. He also served as CEO and later Executive chairman of Myconostica Ltd, a medical technology company spun out from a leading UK university.







Christopher Wilks BSc, ACA, Director

Christopher Wilks BSc, ACA, Director, has considerable experience in the fields of both science and finance. He is currently Chief Financial Officer at Signum Technology, which he co-founded in 2012. Prior to this he was Chief Financial Officer at Sondex plc where he successfully managed their listing on the Main Market of the London Stock Exchange in 2003 and made several post IPO acquisitions. In 2007 Sondex was acquired by GE. After graduating from Durham University with a BSc in Applied Physics and Electronics, Christopher initially joined Marconi Space Systems designing power systems for space craft, he then trained as a Chartered Accountant at Arthur Young (now Ernst & Young). After qualifying as a Chartered Accountant in audit he became a Manager in the Corporate Finance team at Ernst & Young. His intimate understanding of the physics and financial worlds adds valuable insight and expertise.


For information on the management team, please click here

Significant Shareholders



In addition to those disclosed in the Directors Interest section, the Company is aware of the following persons who, at 26 September 2017 have interests in voting rights over 3 percent or more of the issued share capital of the Company:

Major Shareholders Shares   %
Miton Asset Management 49,201,886 18.98
Polymer Holdings* 20,273,475 7.82
Herald Investment Management 13,847,059 5.34
Schroders plc 12,941,115 4.99
Killik & Co LLP 10,318,144 3.98
BlackRock Investment Management 10,000,000 3.86
Prof Max Robinson 9,560,000 3.69
Henderson Global Investors 9,081,777 3.50
NFU Mutual 8,228,569 3.17
Bony OCS 8,010,663 3.09


* Graeme Speirs, a non-executive director of the company, is interested in Polymer Holdings Limited's shareholding in the company as set out above. In addition to his interest in the ordinary shares of the company held by Polymer Holdings Limited set out above, Mr Speirs holds an additional 3,494,940 ordinary shares in the company directly.

Neither the Directors nor any substantial Shareholders have different voting rights to other holders of the share capital of the Company.

This section was last updated on: 26 September 2017

Investor Contacts



Dr Arnab Basu
Chief Executive Officer
Reporting Accountants and Auditors
1 Sovereign Square
Sovereign Street

Company Secretary/ 
In-House Counsel
Derek Bulmer

Lawyers to the Company
Eversheds LLP
Bridgewater Place
Water Lane
LS11 5DR

Registered Office
Thomas Wright Way
TS21 3FD
Link Asset Services
The Registry
34 Beckenham Road

Financial Adviser, 
Nominated Adviser and Joint Broker
Cenkos Securities plc
6.7.8 Token House Yard

Joint Broker
Cantor Fitzgerald Europe
One Churchill Place
Canary Wharf
E14 5RB

Financial PR Advisers
Luther Pendragon Ltd
Second Floor 
48 Gracechurch Street



Columns Including KMK


Market Reports Including KMK

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use